Kezar Life Sciences (NASDAQ:KZR) Posts Earnings Results, Misses Expectations By $0.60 EPS

Kezar Life Sciences (NASDAQ:KZR) announced its quarterly earnings data on Tuesday. The company reported ($1.99) EPS for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.60), FiscalAI reports.

Kezar Life Sciences Stock Down 0.3%

KZR stock opened at $7.40 on Thursday. The company has a market cap of $54.55 million, a price-to-earnings ratio of -0.88 and a beta of 0.53. Kezar Life Sciences has a twelve month low of $3.53 and a twelve month high of $7.55. The business has a 50 day moving average price of $6.59 and a two-hundred day moving average price of $5.97.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kezar Life Sciences in a research note on Monday, December 22nd. Four research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Kezar Life Sciences presently has an average rating of “Reduce” and an average price target of $6.00.

Institutional Investors Weigh In On Kezar Life Sciences

Several large investors have recently made changes to their positions in KZR. Landscape Capital Management L.L.C. bought a new position in shares of Kezar Life Sciences in the third quarter valued at $51,000. Woodline Partners LP acquired a new stake in Kezar Life Sciences in the first quarter valued at $125,000. Torno Capital LLC acquired a new stake in Kezar Life Sciences in the fourth quarter valued at $126,000. Dimensional Fund Advisors LP grew its position in shares of Kezar Life Sciences by 14.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock valued at $167,000 after acquiring an additional 3,312 shares during the period. Finally, State Street Corp grew its position in shares of Kezar Life Sciences by 28.4% in the 4th quarter. State Street Corp now owns 27,093 shares of the company’s stock valued at $170,000 after acquiring an additional 6,000 shares during the period. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.